Tema ETFs’s Denali Therapeutics DNLI Stock Holding History

Tema ETFs’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,174	Closed	-$212K	–	520
2025 Q2	$212K	Hold	15,174	–	–	0.06%	162
2025 Q1	$206K	Buy	+15,174	New	+$291K	0.06%	139

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tema ETFs's DNLI Position: Q3 2025 in Review

Tema ETFs sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 15,174 shares — an estimated $212K sold.

Tema ETFs first reported a position in DNLI in Q1 2025 and held it in 2 quarters. The position peaked at $212K in Q2 2025. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

Tema ETFs reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
Tema ETFs sold 15,174 Denali Therapeutics shares in Q3 2025, an estimated $212K.
Tema ETFs first reported a position in Denali Therapeutics in Q1 2025 and held it in 2 quarters.
Tema ETFs's Denali Therapeutics position peaked at $212K in Q2 2025.
240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Tema ETFs's 13F filing for Q3 2025, filed 24 Oct 2025.